Half life atenolol
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that atenolol has an elimination half-life of approximately 6 to 10 hours in healthy individuals, which can be significantly prolonged in patients with renal impairment.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Half-Life of Atenolol: A Comprehensive Overview
Introduction to Atenolol and Its Pharmacokinetics
Atenolol is a cardioselective beta-blocker commonly used to manage hypertension and other cardiovascular conditions. Understanding its pharmacokinetics, particularly its half-life, is crucial for optimizing its therapeutic efficacy and dosing regimen.
Elimination Half-Life of Atenolol
General Population
The elimination half-life of atenolol in healthy individuals has been reported to vary between 6 to 10 hours. This range is supported by multiple studies, which indicate that the mean elimination half-life is approximately 6.06 ± 2.02 hours, while other studies suggest a slightly longer half-life of around 9 to 10 hours . This variability can be attributed to differences in study design, population, and measurement techniques.
Impact of Renal Function
Atenolol is primarily excreted unchanged via the kidneys, making renal function a significant factor in its elimination. In patients with normal renal function, the half-life remains within the typical range of 6 to 10 hours . However, in patients with impaired renal function, the half-life of atenolol is markedly prolonged. For instance, in patients with severe renal impairment (creatinine clearance < 5 ml/min), the half-life can extend up to 73.4 ± 28.8 hours. This necessitates dosage adjustments to avoid drug accumulation and potential toxicity.
Hemodialysis and Peritoneal Dialysis
In patients undergoing hemodialysis, the half-life of atenolol is significantly reduced during the dialysis session but increases again post-dialysis. The apparent plasma half-life during dialysis can drop to around 7.5 ± 3.7 hours, but it returns to approximately 51.2 ± 17.3 hours after the session. This indicates that while hemodialysis can effectively reduce atenolol levels temporarily, the drug's elimination is still prolonged overall. There is limited data on the effects of peritoneal dialysis on atenolol's half-life, but it is expected to be similarly prolonged due to reduced renal clearance.
Pediatric Population
In children, the pharmacokinetics of atenolol show a slightly shorter terminal elimination half-life compared to adults. Studies indicate a mean half-life of 4.56 ± 1.05 hours in pediatric patients, suggesting that children may require more frequent dosing or adjusted doses to maintain therapeutic levels.
Clinical Implications
Dosing Frequency
The relatively long half-life of atenolol in individuals with normal renal function allows for once-daily dosing, which is convenient for patients and helps ensure compliance. This dosing regimen provides effective 24-hour coverage for managing hypertension and other cardiovascular conditions.
Renal Impairment Considerations
For patients with renal impairment, careful monitoring and dose adjustments are essential. The significant prolongation of atenolol's half-life in these patients underscores the need for individualized dosing strategies to prevent adverse effects .
Dialysis Patients
In patients undergoing dialysis, atenolol dosing should be carefully timed and adjusted based on the dialysis schedule and the observed pharmacokinetic changes. This approach helps maintain therapeutic efficacy while minimizing the risk of drug accumulation .
Conclusion
Atenolol's elimination half-life varies significantly based on renal function and patient demographics. While the typical half-life in healthy individuals ranges from 6 to 10 hours, it can be substantially prolonged in patients with renal impairment. Understanding these variations is crucial for optimizing atenolol therapy, ensuring effective blood pressure control, and minimizing potential side effects.
Sources and full results
Most relevant research papers on this topic
